Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Georgia Koutsou"'
Autor:
Elvira-Maria Arvanitou, Pigi Argyriadou, Georgia Koutsou, Apostolos Ampatzoglou, Alexander Chatzigeorgiou
Publikováno v:
2022 48th Euromicro Conference on Software Engineering and Advanced Applications (SEAA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84a31789fb061b46029ec3cddd8253d0
https://doi.org/10.1109/seaa56994.2022.00050
https://doi.org/10.1109/seaa56994.2022.00050
Autor:
Isabella Elias Yonezawa Ogusuku, Vera Herbel, Simon Lennartz, Caroline Brandes, Eva Argiro, Caroline Fabian, Carola Hauck, Conny Hoogstraten, Sabrina Veld, Lois Hageman, Karin Teppert, Georgia Koutsoumpli, Marieke Griffioen, Nadine Mockel-Tenbrinck, Thomas Schaser, Rosa de Groot, Ian C.D. Johnston, Dominik Lock
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 2, Pp 101224- (2024)
Acute myeloid leukemia (AML) is a heterogeneous malignancy that requires further therapeutic improvement, especially for the elderly and for subgroups with poor prognosis. A recently discovered T cell receptor (TCR) targeting mutant nucleophosmin 1 (
Externí odkaz:
https://doaj.org/article/722f01dd698746e597d61bf1c55d549c
Autor:
Nadine E. Struckman, Rob C. M. de Jong, M. Willy Honders, Sophie-Anne I. Smith, Dyantha I. van der Lee, Georgia Koutsoumpli, Arnoud H. de Ru, Jan-Henrik Mikesch, Peter A. van Veelen, J. H. Frederik Falkenburg, Marieke Griffioen
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1086 (2024)
DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 and 2 (IDH1/2) are genes involved in epigenetic regulation, each mutated in 7–23% of patients with acute myeloid leukemia. Here, we investigated whether hotspot mutations in these gen
Externí odkaz:
https://doaj.org/article/73ecba212d1b405385901b5d4c3917af
Autor:
Georgia Koutsoumpli, Peng Peng Ip, Ilona Schepel, Baukje Nynke Hoogeboom, Annemarie Boerma, Toos Daemen
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, Vol 7 (2019)
Background: Antigen-specific T cell immune responses play a pivotal role in resolving acute and chronic hepatitis C virus (HCV) infections. Currently, no prophylactic or therapeutic vaccines against HCV are available. We previously demonstrated the p
Externí odkaz:
https://doaj.org/article/4b511760a15548edb19b4db2e018ff2d